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Although arterial hypertension is less common in children than in adults, there is growing concern about
elevated blood pressure (BP) in children and adolescents not only because of the association of elevated
values with the overweight epidemic, but also as cardiovascular functions are determined in childhood and
track into adulthood. The purpose of the review is to discuss new aspects of childhood hypertension.
Recent findings
Guidelines advocate determining BP in children as part of routine health maintenance. This
recommendation was recently subject to review by the US Preventive Services Task Force. It was concluded
that evidence is insufficient to assess the benefits of this screening. In our opinion, however, assessing BP is
part of any thorough physical examination.
Sophisticated approaches demonstrate the role of sympathetic nervous system overdrive in the field of
sympathetic cardiovascular modulation of childhood arterial hypertension.
Summary
Elevated BP in children is increasing in frequency and is now recognized as having relevant short-term and
long-term consequences. Although efforts to address the childhood overweight epidemic may eventually
reduce the number of young patients with hypertension, improved therapies for childhood hypertension
also offer the potential for preventing or ameliorating early cardiovascular disease.
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Arterial hypertension affects about 20% of adults
and is a leading cause of morbidity and mortality
[1]. Although hypertension is less common in chil-
dren than in adults, there is growing concern about
elevated blood pressure (BP) and hypertension in
children and adolescents because of the association
of elevated BP with the overweight epidemic [2,3].
Moreover, it has been hypothesized that cardiovas-
cular functions are determined in childhood and
track into adulthood. Children with high BP values
have a greater risk to have high (or too high) BP
levels in adulthood, as indicated by the fact that
almost half of adults with arterial hypertension
had high BP values in childhood [3–5]. Tracking
of BP begins in early childhood, at about the age
of 5 years [6]. Consequently, prevention of adult
cardiovascular diseases should begin early in child-
hood by counseling healthy lifestyle and avoiding
preventable cardiovascular risk factors [3,7
&
].
Screening for high BP at regular intervals in child-
hood is currently a matter of debate and will be
further discussed in this review together with theht © 2015 Wolters Kluwe
rs Kluwer Health, Inc. All rights resedefinition of arterial hypertension, its association
with sympathetic nervous system overactivation
and its consequences.Measurement of blood pressure and
screening for hypertension in childhood
In childhood, the recommended method for BP
assessment is auscultatory with Korotkoff 1 applied
for SBP and Korotkoff 5 applied for DBP.
If an oscillometric device is used, the monitor
needs to be validated; additionally, if hypertensionr Health, Inc. All rights reserved.
rved. www.co-cardiology.com
KEY POINTS
 Guidelines advocate determining blood pressure in
children during each healthcare episode. This
recommendation was recently subject to review by the
US Preventive Services Task Force, which concluded
that evidence is insufficient to assess the benefits of
screening in apparently healthy children
and adolescents.
 There is a renewed interest in the field of sympathetic
cardiovascular modulation of prehypertension, primary
hypertension and chronic kidney disease.
 The syndrome in childhood hypertensive
encephalopathy appears to be a form of posterior
reversible encephalopathy syndrome, a reversible
clinicoradiologic entity characterized by insidious onset
of headache, confusion, visual disturbances and
seizures associated with brain edema, which
predominates in the posterior areas and in the white
matter on imaging.
 Considering the high prevalence of secondary
hypertension with a rather well-identified mechanism
underlying high blood pressure in children and
adolescents, a targeted approach to therapy is
commonly advocated in an effort to maximize benefit.
Hypertensionis detected by the oscillometric method, it needs to
be confirmed using the auscultatory method.
Finally, the appropriate cuff size according to arm
width (40% of the arm circumference) and length
(48 cm, 612 cm, 918 cm, 1024 cm, to cover
80–100% of the individual’s arm circumference)
should be used [8]. Arterial hypertension in child-
hood is defined by at least three measurements
at different times above the 95th centile adapted
for age, height and sex. White coat hypertension
and, more rarely, masked hypertension should be
ruled out by 24-h ambulatory BP measurement
(ABPM), particularly in older children. ABPM can
nowadays be easily performed from the age of about
5 years onward and normal values for children are
available [8].
In many industrialized countries, current guide-
lines advocate determining BP in children after the
age of 3 years during each healthcare visit to screen
for arterial hypertension [8,9]. This rather logical
and intuitive suggestion was recently subject to
intense scientific review by the US Preventive Serv-
ices Task Force. The conclusion provided in the
report is that ‘current evidence is insufficient to
assess the balance of benefits and harms of screening
for elevated BP in apparently healthy children and
adolescents to prevent subsequent cardiovascular
disease in childhood or adulthood’ [10]. This con-
clusion, which is largely based on the lack of data Copyright © 2015 Wolters Kluwer 
404 www.co-cardiology.comfrom longitudinal, randomized trials to support this
practice, has been widely disputed [11
&
,12–14,15
&
].
In our opinion, this review fails to acknowledge
thatmeasurement of BP, a cheap and integral part of
any careful physical examination, is too infre-
quently recorded in everyday pediatric practice. In
addition, in many countries routine metabolic
blood screenings (more invasive and expensive)
for inherited disorders that are rarer than arterial
hypertension are performed in newborn infants.
Furthermore, the limitations of the analysis per-
formed by the US Preventive Services Task Force
deserve some comment. In the following, we aim
at discussing these three issues.
Physicians are trained to monitor the develop-
ment and the growth of children and youth using,
among others, weight, height, head circumference,
body temperature, respiratory rate, pulse rate and
BP. Pediatric reference tables for these parameters,
including BP, are available worldwide. Meanwhile,
pediatricians can avoid unfriendly BP tables and
interpret user-friendly BP measurements by using
a mnemonic formula, online calculators or appli-
cations for smartphones [16,17].
BP measurement in children is part of routine
healthmaintenance and is associated with no harm.
In children with conditions increasing the risk of
high BP – including premature birth, low birth
weight, congenital heart disease, kidney diseases
and treatment with drugs known to raise BP –
checks begin during infancy (Table 1). Further fac-
tors predisposing to arterial hypertension in school-
age children and adolescents are excessive body
weight and a family history of elevated BP. In every-
day clinical practice, BP is infrequently recorded in
children and adolescents and, in our opinion, the
conclusions raised by the US Preventive Services
Task Force indirectly suggest that determination
of BP is often unnecessary in children and adoles-
cents. Our experience at a tertiary referral center
with a catchment area of, approximately, one
million people is in contrast to this conclusion. At
this center, two or more asymptomatic cases of
severe secondary hypertension with relevant target
organ damage are encountered every year, support-
ing the notion that secondary arterial hypertension
may go unrecognized in childhood [18].
Nowadays, most countries provide an expanded
but rather expensive universal newborn metabolic
screening for conditions such as adrenal hyperpla-
sia, cystic fibrosis, galactosemia, hypothyroidism
and phenylketonuria [19]. The frequency of arterial
hypertension in children and adolescents is con-
sidered to be one in 50–100 individuals [8,9]. Thus,
it appears surprising that rather expensive screening
recommendations are used to identify rare or veryHealth, Inc. All rights reserved.
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Table 1. Conditions under which children 3 years of age
or less should have blood pressure measured
Recurrent urinary tract infections
Hematuria or proteinuria
Known renal disease or urologic malformations
Family history of congenital renal disease
History of prematurity, very low birth weight, neonatal compli-
cations requiring intensive care
Congenital heart disease (repaired or not)
Malignancy
Solid organ or bone marrow transplant
Systemic diseases possibly associated with arterial hypertension
(e.g., neurofibromatosis, tuberous sclerosis, Marfan syndrome,
William–Beuren syndrome)
Management with drugs known to raise blood pressure
Arterial hypertension in children Santi et al.rare inherited diseases and that measuring BP at
regular intervals is not advised for a quite common
condition such as arterial hypertension, which is a
substantial cause of heart hypertrophy, arterial stiff-
ening and further organ damage that might be
prevented by nonpharmacological and pharmaco-
logical intervention [20–23].
Finally, only 35 articles (out of 1000 potentially
relevant articles) were included in the final
analysis. As noted by two commentaries [13,15
&
],
the Task Force recommendation fails to consider
a considerable body of literature that includes
relevant observational studies, specifically those
addressing intermediate outcomes associated with
childhood arterial hypertension, such as carotid
artery thickening, left ventricular hypertrophy
and urinary protein excretion [20–23].
We believe that the recommendation of the
Task Force is inconclusive and flawed because
the evidence was too narrowly selected, excluding
short-term and relevant observational studies.
Hence, we still advise routine screening for high
BP at all well child visits, and hope that data from
large pediatric cohorts with a long-term follow-up
will support our impression.Sympathetic nervous system abnormalities in
children and adolescents with tendency
toward essential hypertension and kidney
disease
The sympathetic arm of the autonomic nervous
system, which is mainly implicated in the homeo-
stasis of involuntary processes in response to stress-
ful or emergency situations, plays a critical role in
the regulation of BP [24]. Its importance in the
short-term regulation of arterial pressure via barore-
flex mechanisms is well recognized. However, the Copyright © 2015 Wolters Kluwe
0268-4705 Copyright  2015 Wolters Kluwer Health, Inc. All rights reserole of the sympathetic nervous system in longer-
term (days, months and years) BP modulation has
been a focus of consideration since the 1970s [24].
Various studies have established that young partici-
pants with mild hypertension or normotensive off-
spring of hypertensive families often exhibit high
heart rate and elevated cardiac output. Furthermore,
several sympathetic-mediated abnormalities have
been reported in these participants, including: a
disturbed BP regulation after standing; an altered
baroreceptor function; an exaggerated sensitivity of
the forearm vasculature to exogenous norepi-
nephrine or of the renal vessels to psychological
stimuli; an increased responsiveness of BP to mental
stress or dietary potassium restriction; and high
circulating catecholamine concentrations during
stress [24]. Approximately 30 years ago, a coauthor
extensively investigated the BP responses to a step-
wise increase in plasma norepinephrine or angio-
tensin II concentrations induced by exogenous
infusions of the vasopressors in young adult patients
withmild primary hypertension (and a normal BMI)
and in normotensive participants with a negative or
positive family history of essential hypertension.
Patients and participants with positive history dif-
fered from those with negative history of hyperten-
sion by a decreased pressor dose of infused
norepinephrine and by a different relationship
between norepinephrine-induced changes in BP
and concomitant plasma norepinephrine levels. In
contrast, the pressor dose of infused angiotensin II
and the relation between stepwise increasing plasma
angiotensin II levels and induced changes in BP was
similar in hypertensive patients and in the two
groups of normotensive participants (Fig. 1). The
aforementioned data indicate the existence of a
selectively disturbed noradrenergic BP control in
patients with mild primary hypertension and in
normotensive offspring of hypertensive families
[25,26].
Since then, sophisticated biochemical (norepi-
nephrine spillover), neurophysiological (direct
recording of muscle sympathetic nerve traffic) and
bioengineering (power spectral analysis of the heart
rate signal) approaches have been developed to
assess human sympathetic function, allowing new
insights in this field [24,27,28]. These data demon-
strate a renewed interest of investigators in the field
of sympathetic cardiovascular modulation of arte-
rial hypertension and chronic kidney disease. Cur-
rently available results indicate the following:
sympathetic nervous system overdrive is often
modulated by a genetic background; sympathetic
overdrive appears very early in the course of primary
hypertension; the degree of the sympathetic over-
activation is directly related to the severity ofr Health, Inc. All rights reserved.
rved. www.co-cardiology.com 405
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FIGURE 1. Blood pressure responses to a stepwise increase in plasma norepinephrine or angiotensin II concentrations
induced by exogenous infusions of the vasopressors in 25 young adult patients (black) with mild primary hypertension (and a
normal BMI) and in normotensive participants with a negative (N¼25; light gray) or with a positive (N¼25; dark gray)
family history of essential hypertension. Patients and participants with positive history differed from those with negative history
of hypertension by a decreased pressor dose of infused norepinephrine (right lower panel) and by a different relationship
between norepinephrine-induced changes in blood pressure and concomitant plasma norepinephrine levels (right upper
panel). In contrast, the pressor dose of infused angiotensin II (left lower panel) and the relation between stepwise increasing
plasma angiotensin II levels and induced changes in blood pressure (left upper panel) were similar in hypertensive patients
and in the two groups of normotensive participants. The bars denote SEM.
Hypertensionprimary hypertension; adrenergic activation dis-
plays an adverse impact on end-organ damage
and cardiovascular morbidity; in chronic kidney
disease, sympathetic activation occurs both in the
earlier and in the more advanced clinical stages of
the disease and is directly correlated to the severity
of the disease; finally, overweight and weight gain
are associatedwith increased sympathetic overdrive.
Catheter-based radiofrequency ablation of renal
sympathetic nerves, also known as renal denerva-
tion, is a new, apparently promising, strategy that
may substantially lower BP in patients with drug-
resistant hypertension. Regrettably, the utility of
renal denervation has not been proven in drug-
resistant arterial hypertension [29
&&
].Short-term and long-term consequences of
arterial hypertension in childhood
Cardiovascular diseases such as stroke or myocardial
infarction occur after several years of arterial Copyright © 2015 Wolters Kluwer 
406 www.co-cardiology.comhypertension. Consequently, these cardiovascular
complications first appear in adulthood, indicating
that is not possible to directly link BP levels in
childhood with cardiovascular disease risk in adult-
hood. Nevertheless, a correlation between BP and
surrogate markers of target-organ damage, such as
left ventricular hypertrophy, arterial stiffness or
increased urinary protein excretion, is demonstrable
in children with arterial hypertension [3].
Severe hypertension in childhood mainly results
from secondary causes, such as cardiac or renal dis-
ease. Acute symptoms or organ failure are normally
not present in children with primary hypertension
because in this age group primary hypertension is
rather mild. Primary hypertension, as in adults, is
mainly asymptomatic, or shows few symptoms such
as headaches, shortness of breath, epistaxis, and
changes in behavior or school performance.
Posterior reversible encephalopathy syndrome
is a potentially reversible clinicoradiological entity
characterized by insidious onset of headache,Health, Inc. All rights reserved.
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Arterial hypertension in children Santi et al.confusion, visual disturbances and seizures associ-
ated with brain edema, which predominates in the
posterior white matter. Two major factors predis-
pose to this entity in childhood: an acute and severe
increase in BP and calcineurin inhibitors. Nephrotic
syndrome and acute glomerulonephritides such as
postinfectious glomerulonephritis, Immunoglobu-
lin A (IgA) or purpura Scho¨nlein-Henoch nephritis
are the most common underlying conditions. As
previously stated, altered consciousness (coma, stu-
por, lethargy and confusion), seizures, headache
and visual disturbances are the most distinctive
clinical presentation. Symptoms usually develop
abruptly and resolve soon with proper management
(BP reduction or discontinuation of the causative
medication). Cranial MRI is the imagingmodality of
choice for detecting the entity [30]. The underlying
pathophysiologic process appears to be a break-
through of cerebral blood flow autoregulation, caus-
ing vasogenic edema.
The most significant long-term consequence of
elevatedBP inchildhood is theongoinghypertension
into adulthood (tracking of BP [5]), therefore causing
cardiovascular, cerebrovascular and renaldisease later
in life [3,5,6,21,22]. The most evident target-organ
damage during childhood and adolescence is left
ventricular hypertrophy [8,9]. About 50% of children
and adolescents with arterial hypertension have a left
ventricular mass index (LVMI) more than the 90th
centile and 14% have a LVMI more than the 99th
centile [31]. An association between LVMI and sys-
tolic ambulatory BP has also been demonstrated in
children; this association is stronger thanwith casual
BP measurement [32,33]. Children with white coat
hypertension have increased LVMI, representing an
intermediate state between hypertensive and normo-
tensive children [34]. Furthermore, prehypertension
(BP values between the 90th and 95th centiles)
represents an intermediate risk for the development
of left ventricular hypertrophy [35].
Hypertensive retinopathy may be found in
children with arterial hypertension. Retinal changes
with retinal artery narrowing can be observed in
children as young as 6–8 years of age.
Preclinical atherosclerosis is assessed by measur-
ing carotid intima–media thickness (cIMT). Several
reports document the dependent relationship
between cIMT values and childhood BP [22]. Other
factors contributing to increased cIMT are BMI and
low-density lipoprotein cholesterol [22,23]. Postmor-
tem analysis in the Bogalusa Heart Study revealed
that childhood SBP was correlated with fatty streaks
and fibrous plaques in young adults [36]. Parameters
of arterial distensibility, left ventricular mass, BMI
and sedentary lifestyle in childhood were precursors
of adult hypertension and target organ damage Copyright © 2015 Wolters Kluwe
0268-4705 Copyright  2015 Wolters Kluwer Health, Inc. All rights rese[37,38
&&
,39,40
&
]. Again, these data confirm that car-
diovascular risk factors have origins in childhood.
Another surrogate marker of impaired vascular func-
tion and arterial wall changes (i.e., calcification or
atherosclerosis) is arterial stiffness,which is increased
in childhood hypertension [41]. Obesity and arterial
hypertension have a detrimental effect on arterial
stiffness [42].
Childhood hypertension can also impair cogni-
tive function and cerebral vascular reactivity. Lande
et al. [43,44] reported an association between arterial
hypertension and decreased performance on tests of
neurocognitive function, which should be adjusted
for potential confounding effects of sleep disordered
breathing [45]. Additionally, Adams et al. [46]
reported learning and attention problems among
children with pediatric primary hypertension.
Finally, microalbuminuria is a marker of early renal
damage. Childhood hypertension seems to affect
microalbuminuria in children [47].Treatment of arterial hypertension in
childhood
Over the last years, management of childhood high
BP has been addressed more rigorously than in the
past, resulting in clearer consensus recommen-
dations pertaining to appropriate drugmanagement.
In children and adolescents with uncomplicated
primary hypertension, the goal of therapy should
be BP reduction to less than the 95th percentile
(despite therapeutic lifestyle modification). In the
setting of concurrent diseases, such as diabetes mel-
litus, or target end-organ damage, BP should be low-
ered to less than the 90th percentile. On the basis of
evidence thatmore aggressive controlmay be especi-
ally beneficial in slowing renal functional decline in
nephropathic paticipants, the European guidelines
advocate for more rigorous BP control, with target
values less than the 75th percentile in children
with chronic kidney disease and less than the 50th
percentile in children with both kidney disease and
increased urinary protein excretion [8].
Obviously, participants with asymptomatic
primary hypertension may be managed successfully
with lifestyle interventions, including extensive
counseling regarding the importance of appropriate
dietary choices, regular exercise and weight loss.
Unfortunately, success may be arduous to achieve
with this approach alone and antihypertensive
medication is sometimes required.
Considering the high prevalence of secondary
hypertension with a rather well-identified mechan-
ism underlying high BP in children and adolescents,
a targeted approach to therapy is commonly advo-
cated in an effort to maximize benefit. In patientsr Health, Inc. All rights reserved.
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Hypertensionwith concomitant diseases a specific drug may be
particularly beneficial. For example, b-adrenergic
blockade is advocated in children with coarctation
of the aorta in the period before repair, as these
agents reduce the degree of acute postintervention
hypertension. In cases with persistent hypertension
after correction, b-blockade is usually continued,
although treatment with blockers of the renin–
angiotensin–aldosterone system may also be well
tolerated and effective in these patients. Further-
more, in children with diabetes mellitus or kidney
disease, therapy with a blocker of the renin–angio-
tensin–aldosterone system is advised, especially in
cases with pathological urinary protein excretion.
In patients affected with a chronic parenchymal
kidney disease, the most common indication for
antihypertensive drug management in childhood, Copyright © 2015 Wolters Kluwer 
Table 2. Antihypertensive drugs that may be administered once
in pediatric patients with chronic kidney disease
Class Agent 10–25
Thiazide diuretics
Chlortalidonea,b 6–12
Hydrochlorothiazidea,b 6–12
Potassium sparing diuretics
Amiloridea 1.3–2.5
Spironolactone 12–25
Triamterene 12–25
b-adrenergic-blockers
Bisoprolola 1.2–2.5
Atenolol 12–25
Metoprolol 10–25
Calcium-channel blockers
Amlodipinea 2.5–5
Lercanidipinea,b 5–10
Angiotensin II antagonists
Candesartana,b 4–8
Irbesartana 37–75
Losartan 12–25
Valsartan 5–40
Converting enzyme inhibitors
Benazepril 2.5–5.0
Fosinopril 1.3–2.5
Lisinoprilb 2.5–10
Quinapril 2.5–5.0
Ramiprila 1.3–2.5
aThese drugs are very popular at our institutions.
bFavorable palatability. The prescription of drugs with sustained-release technologie
dose’ is progressively escalated up to the ‘maximum dose’ every 3–6 weeks.
408 www.co-cardiology.comblocking the renin–angiotensin–aldosterone sys-
tem is very often insufficient to attain goal BP. In
these cases, a diuretic (or a calcium channel-blocker)
is added (a b-blocker is added only if the BP goal is
still not achieved by combining three drugs) [8].
Table 2 shows the most frequently used antihyper-
tensive drugs in childhood.
Finally, it is also important to consider potential
adverse effects prior to initiating therapy. For
example, noncardioselective b-adrenergic blockers
are generally avoided in participants affected with
reactive airway disease due to an increased risk of
bronchospasm. On the other hand, there are signifi-
cant fetal risks associated with the use of blockers of
the renin–angiotensin–aldosterone during preg-
nancy (first trimester exposure might increase the
risk of cardiovascular and central nervous systemHealth, Inc. All rights reserved.
a day in the outpatient management of arterial hypertension
Daily dose (mg)
Body weight (kg)
25–40 >40
12–25 25–50
12–25 25–50
2.5–5.0 5.0–20
12–100 50–200
12–100 50–200
2.5–5.0 5.0–10
25–100 100–200
25–100 100–200
5–10 10–20
10–20 20–40
8–16 16–32
75–150 150–300
[25]–100 [50]–100
10–80 40–160
5.0–10 10–20 [40&]
2.5–10 5.0–20 [40&]
5.0–20 10–30 [40&]
5.0–10 10–20 [40&]
2.5–10 5.0–20
s that can reduce dosing frequency to once a day is not advised. The ‘starting
Volume 30  Number 4  July 2015
Arterial hypertension in children Santi et al.malformations; second and third trimester exposure
interferes with fetal renal function, decreasing fetal
urine production and resulting in the fetal renin–
angiotensin system blockade syndrome, which is
characterized by oligohydramnios, fetal pulmonary
hypoplasia and deformational abnormalities) [48].
Consequently, discontinuation of these drugs is
advised in women who present in early pregnancy,
with substitution of an alternate agent if necessary.
Furthermore, avoidance of drugs that block the
renin–angiotensin–aldosterone system is suggested
in women of childbearing age, for whom there are
other antihypertensive drugs that would be well
tolerated by the fetus.CONCLUSION
Adult hypertension often begins in childhood.
However, overt hypertension is noticeably different
in childhood than it is in adults, and requires evalu-
ation and management reflecting differences in the
underlying pathophysiology. Although manifest
cardiovascular disease related to hypertension is rare
during childhood, early onset of this condition
undoubtedly contributes to an acceleration of car-
diovascular disease and target-organ damage,
especially in the presence of the clustering of risk
factors associated with overweight. We still recom-
mend that children over 3 years of age should have
their BP measured as part of routine healthcare.
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